Publications in collaboration with researchers from University of Bari Aldo Moro (11)

2025

  1. Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    Health Policy, Vol. 156

  2. Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis

    Joint Bone Spine, Vol. 92, Núm. 3

  3. Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors

    Rheumatology, Vol. 64, Núm. 4, pp. 1853-1863

2024

  1. Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

    Arthritis Care and Research, Vol. 76, Núm. 11, pp. 1558-1565

  2. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

    RMD Open, Vol. 10, Núm. 3

  3. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 65

  4. Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: A survey

    Rheumatology Advances in Practice, Vol. 8, Núm. 4

  5. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

    Arthritis and Rheumatology, Vol. 76, Núm. 4, pp. 587-598

2023

  1. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

  3. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: Results from the EuroSpA Research Collaboration Network

    RMD Open, Vol. 9, Núm. 4